XML 100 R84.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Commitments and Contingencies (Details) |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 01, 2021 USD ($) | Jun. 21, 2021 USD ($) | Apr. 12, 2021 USD ($) | Mar. 20, 2021 USD ($) shares | May 29, 2020 USD ($) | Mar. 31, 2020 USD ($) shares | Aug. 31, 2021 USD ($) | Jan. 31, 2020 USD ($) | May 31, 2016 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 07, 2021 USD ($) | Jul. 31, 2021 USD ($) | Jun. 30, 2021 USD ($) | Jan. 31, 2021 USD ($) | Feb. 14, 2020 USD ($) | Nov. 01, 2019 USD ($) | Feb. 28, 2015 USD ($)
Rumpus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Up-front fee |  |  | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of aggregated fees |  |  | 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  | 67,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Karbinal Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Supply and distribution commitment, period (in Years) |  |  |  |  |  |  |  |  |  |  |  | 20 years |  |  |  |  |  |  |  |
Percentage of net sales on royalty |  |  |  |  |  |  |  |  |  |  |  | 23.50% |  |  |  |  |  |  |  |
Maximum yearly make-whole payment |  |  |  |  |  |  |  |  |  | $ 2,100,000 |  | $ 2,100,000 |  |  |  |  |  |  |  |
Tris Pharma, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum sales per year |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70,000 |  |  |  |  |
Tris Pharma, Inc. | Karbinal Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum sales per year |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70,000 |  |  |  |  |
Make-whole payment per unit for sales under minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30 |  |  |  |  |
Maximum milestone obligations |  |  |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
First milestone, minimum net revenues |  |  |  |  |  |  | $ 40,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Innovus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued to contingent value rights share holders | shares |  |  |  | 103,190 |  | 123,820 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent value rights amount |  |  |  |  |  | $ 2,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
First milestone |  |  |  | $ 30,000,000.0 |  |  |  |  |  | 24,000,000.0 |  | 24,000,000.0 |  |  |  |  |  |  |  |
Second milestone |  |  |  | 40,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain (loss) from change in fair value of CVR |  |  |  |  |  |  |  |  |  | 44,000 | $ (100,000) |  | $ 900,000 |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  |  |  |  | 300,000 |  | 300,000 |  |  |  | $ 300,000 |  | $ 200,000 |  |
Innovus | University of Iowa Research Foundation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total milestone payments |  |  |  |  |  |  |  |  |  | 200,000 |  | 200,000 |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  |  |  |  | 48,000 |  | 48,000 |  |  |  | $ 100,000 |  |  |  |
Milestone payment payable |  |  |  |  |  |  |  |  |  | 50,000 |  | 50,000 |  |  |  |  |  |  |  |
Milestone payments made | $ 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novalere | Innovus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5
Total milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000
Contingent consideration |  |  |  |  |  |  |  |  |  | 300,000 |  | 300,000 |  |  |  |  |  |  |  |
Prescription Database |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment |  |  |  |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |  |  |  |  |  |
Term of payment |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |
Prescription Database | The Pediatric Portfolio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment |  |  |  |  |  |  |  | $ 600,000 |  |  |  |  |  |  |  |  |  |  |  |
First Pediatric Portfolio Fixed Obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Monthly payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 86,400 |  |  |
Balloon payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000.0 |  |  |
Repayments Of Fixed Obligation |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Second Pediatric Portfolio Fixed Obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Monthly payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 |
Payments For Fixed Obligations To Investor |  | $ 2,800,000 |  |  |  |  |  | $ 210,767 |  |  |  |  |  |  |  |  |  |  |  |
Repayments Of Fixed Obligation |  | 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Inventories | Hikma Pharmaceuticals USA, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment |  |  |  |  |  |  |  |  |  | $ 700,000 |  | 700,000 |  |  |  |  |  |  |  |
Rumpus Earn Out Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Maintenance Fee Payable |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |  |  |
Over Next Six Quarters Commencing September 30, 2021 | Second Pediatric Portfolio Fixed Obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Repayments Of Fixed Obligation |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone 2021 | Innovus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent value rights amount |  |  |  | 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
First milestone |  |  |  | $ 40,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone not met during the year |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |
In-process R&D | Rumpus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Up-front fee |  |  | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of aggregated fees |  |  | 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  | 67,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
In-process R&D | Maximum | Rumpus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  | 67,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
In-process R&D | Denovo Biopharma L L C | Rumpus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  | 101,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Maintenance Fee Payable |  |  | 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Option Fee Payable |  |  | 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
In-process R&D | Johns Hopkins University | Rumpus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  | 1,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum annual royalties |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of revenues on royalty payments |  |  | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
In-process R&D | Beginning 2022 | Johns Hopkins University | Rumpus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum annual royalties |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The amount of annual maintenance fee payable under the agreement. + References No definition available. + Details
Name: | aytu_AnnualMaintenanceFeePayable
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration transferred for transaction cost incurred in asset acquisition. + References No definition available. + Details
Name: | aytu_AssetAcquisitionConsiderationTransferredForTransactionCost
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the information pertaining to for contingent consideration arrangements recognized in connection with an asset purchase, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References No definition available. + Details
Name: | aytu_AssetPurchaseContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of payments for contingent consideration under the business acquisition. + References No definition available. + Details
Name: | aytu_BusinessAcquisitionContingentConsiderationNumberOfPayments
Namespace Prefix: | aytu_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of payment per each sales milestone of contingent consideration of the business acquisition. + References No definition available. + Details
Name: | aytu_BusinessAcquisitionContingentConsiderationPaymentUponEachSalesMilestone
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The first revenue milestone for contingent value rights holders of the business acquisition. + References No definition available. + Details
Name: | aytu_BusinessCombinationContingentValueRightsFirstRevenueMilestone
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights revenue milestone not met during the year. + References No definition available. + Details
Name: | aytu_BusinessCombinationContingentValueRightsRevenueMilestoneNotMetDuringYear
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The second revenue milestone for contingent value rights holders of the business acquisition. + References No definition available. + Details
Name: | aytu_BusinessCombinationContingentValueRightsSecondRevenueMilestone
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The minimum amount of annual royalties that must be generated for one product in the event that minimum sales volume is not generated. + References No definition available. + Details
Name: | aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMinimumAnnualRoyalties
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of net revenues generated for royalty payments, assumed as of the acquisition date. + References No definition available. + Details
Name: | aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesRoyaltyPaymentsPercentageOfRevenues
Namespace Prefix: | aytu_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of balloon payment under contractual obligation. + References No definition available. + Details
Name: | aytu_ContractualObligationBalloonPayment
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of monthly payment under contractual obligation. + References No definition available. + Details
Name: | aytu_ContractualObligationMonthlyPayment
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of gain (loss) from change in fair value of CVR. + References No definition available. + Details
Name: | aytu_GainLossFromChangeInFairValueOfCVR
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payment payable under the license agreement + References No definition available. + Details
Name: | aytu_LicenseAgreementMilestonePaymentPayable
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of license option fee payable under the agreement. + References No definition available. + Details
Name: | aytu_LicenseOptionFeePayable
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of milestones payments made during the period. + References No definition available. + Details
Name: | aytu_MilestonesPaymentsMade
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash outflow for fixed obligation to investor. + References No definition available. + Details
Name: | aytu_PaymentsForFixedObligationsToInvestor
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash outflow for fixed obligations during the period. + References No definition available. + Details
Name: | aytu_RepaymentsOfFixedObligation
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares of stock issued during the period to the contingent value rights holders. + References No definition available. + Details
Name: | aytu_StockIssuedDuringPeriodSharesContingentValueRights
Namespace Prefix: | aytu_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The value of stock issued during the period for contingent value rights. + References No definition available. + Details
Name: | aytu_StockIssuedDuringPeriodValueContingentValueRights
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionAgreementMakeWholePaymentPerUnitForSalesUnderMinimum
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum amount of milestone obligations of the supply and distribution agreement. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum amount of make-whole payment per year under supply and distribution agreement. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionAgreementMaximumYearlyMakeWholePayment
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Th minimum amount of units to be sold per year under supply and distribution agreement. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionAgreementMinimumSalesPerYear
Namespace Prefix: | aytu_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionCommitmentPeriod
Namespace Prefix: | aytu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of net sales that is to be paid in total for royalties under the supply and distribution agreement. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionCommitmentTotalRoyaltyPercentageOfNetSales
Namespace Prefix: | aytu_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 55 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308 + Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of the unrecognized unconditional purchase obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308 + Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=aytu_RumpusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=aytu_KarbinalAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_TrisPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=aytu_UniversityOfIowaResearchFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_NovalereMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=aytu_InnovusPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_ThePediatricPortfolioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_FirstPediatricPortfolioFixedObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_SecondPediatricPortfolioFixedObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=aytu_HikmaPharmaceuticalsUsaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_RumpusEarnOutPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=aytu_OverNextSixQuartersCommencingSeptember302021Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=aytu_Milestone2021Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=aytu_DenovoBiopharmaLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=aytu_JohnsHopkinsUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=aytu_Beginning2022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |